| Literature DB >> 29129717 |
Hai-Tsang Huang1, Dennis Dobrovolsky1, Joshiawa Paulk2, Guang Yang3, Ellen L Weisberg2, Zainab M Doctor1, Dennis L Buckley2, Joong-Heui Cho4, Eunhwa Ko4, Jaebong Jang1, Kun Shi5, Hwan Geun Choi4, James D Griffin6, Ying Li7, Steven P Treon8, Eric S Fischer1, James E Bradner6, Li Tan9, Nathanael S Gray10.
Abstract
Heterobifunctional molecules that recruit E3 ubiquitin ligases, such as cereblon, for targeted protein degradation represent an emerging pharmacological strategy. A major unanswered question is how generally applicable this strategy is to all protein targets. In this study, we designed a multi-kinase degrader by conjugating a highly promiscuous kinase inhibitor with a cereblon-binding ligand, and used quantitative proteomics to discover 28 kinases, including BTK, PTK2, PTK2B, FLT3, AURKA, AURKB, TEC, ULK1, ITK, and nine members of the CDK family, as degradable. This set of kinases is only a fraction of the intracellular targets bound by the degrader, demonstrating that successful degradation requires more than target engagement. The results guided us to develop selective degraders for FLT3 and BTK, with potentials to improve disease treatment. Together, this study demonstrates an efficient approach to triage a gene family of interest to identify readily degradable targets for further studies and pre-clinical developments.Entities:
Keywords: BTK; FLT3; chemoproteomics; drug design; kinase; protein degradation
Mesh:
Substances:
Year: 2017 PMID: 29129717 PMCID: PMC6427047 DOI: 10.1016/j.chembiol.2017.10.005
Source DB: PubMed Journal: Cell Chem Biol ISSN: 2451-9448 Impact factor: 8.116